Evidence map›Paper›PMID 41323187›Full record

ArticleRadiology case reports2026

Diagnostic challenges in bleeding renal tumors: A ruptured papillary renal cell carcinoma showing regression followed by progression.

Rika Yoshida, Yuki Komatsubara, Takeshi Yoshizako, Kazutaka Mitani, Kohei Ogawa, Koichiro Wada, Asuka Araki, Yasushi Kaji

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Radiology case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Rika YoshidaDepartment of Radiology, Shimane University, Faculty of Medicine, 89-1, Izumo, Shimane 693-8501, Japan.
Yuki KomatsubaraDepartment of Radiology, Shimane University, Faculty of Medicine, 89-1, Izumo, Shimane 693-8501, Japan.
Takeshi YoshizakoDepartment of Radiology, Shimane University, Faculty of Medicine, 89-1, Izumo, Shimane 693-8501, Japan.
Kazutaka MitaniDepartment of Urology, Shimane University, Faculty of Medicine, 89-1, Izumo, Shimane 693-8501, Japan.
Kohei OgawaDepartment of Urology, Shimane University, Faculty of Medicine, 89-1, Izumo, Shimane 693-8501, Japan.
Koichiro WadaDepartment of Urology, Shimane University, Faculty of Medicine, 89-1, Izumo, Shimane 693-8501, Japan.
Asuka ArakiDepartment of Organ Pathology, Shimane University, Faculty of Medicine, 89-1, Izumo, Shimane 693-8501, Japan.
Yasushi KajiDepartment of Radiology, Shimane University, Faculty of Medicine, 89-1, Izumo, Shimane 693-8501, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A man in his 60s with a history of a right renal tumor presented with right abdominal pain. Imaging revealed tumor rupture with retroperitoneal hemorrhage. Although initial conservative treatment led to temporary tumor shrinkage, significant regrowth occurred over the next 4 years, necessitating radical nephrectomy. The pathological diagnosis was papillary renal cell carcinoma (PRCC). This case highlights the intrinsic fragility of PRCC-a type of renal cancer prone to spontaneous bleeding. It also highlights the importance of considering renal cell carcinoma in the differential diagnosis of renal hemorrhage, not just angiomyolipoma. Notably, PRCC can rupture even with subtle imaging findings. Crucially, this case emphasizes the need for strict and long-term follow-up in conservatively managed ruptured renal tumors because apparent regression does not guarantee complete resolution.

Indexed as

Conservative treatmentLong-term follow-upPapillary renal cell carcinomaRe-enlargementTumor rupture

Identifiers

PMID41323187
PMCPMC12657272

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.